Can a cell ther­a­py treat mus­cu­lar dy­s­tro­phy? A Ger­man bil­lion­aire's an­ti-ag­ing start­up is try­ing to find out

4 years ago
Startups

Covid-19 roundup: CDC ad­vi­sors find like­ly link be­tween mR­NA vac­cines and rare cas­es of heart in­flam­ma­tion; NIH ...

4 years ago
Coronavirus

Monte Rosa takes this week's IPO lead as a nine-fig­ure raise push­es in­dus­try to­tal past $9B

4 years ago
Financing

What con­tro­ver­sy? Eli Lil­ly plots Alzheimer's BLA fil­ing lat­er this year as FDA taps more an­ti-amy­loid drugs as ...

4 years ago
FDA+

EQRx and Ex­sci­en­tia, a pair of self-styled dis­rup­tors, team up to over­turn the drug pric­ing ap­ple cart

4 years ago
Deals

Arie Bellde­grun's Vi­da Ven­tures goes back to the well with $825M mega­fund and its eyes set on more in­no­v­a­tive meds

4 years ago
Financing

Mul­ti­va­lent mR­NA vac­cines, I/O 3.0, long-act­ing HIV drugs: The $46B game is on for the new Glax­o­SmithK­line

4 years ago
Pharma

Ar­cus de­clares cryp­tic in­ter­im win for close­ly watched an­ti-TIG­IT drug, but you'll have to wait for the da­ta

4 years ago
R&D

Hutchmed/As­traZeneca lung can­cer drug gets OK in Chi­na; Enan­ta re­ports PhIb da­ta for their oral he­pati­tis B pro­gram

4 years ago
News Briefing

Out­spo­ken drug pric­ing re­searcher Pe­ter Bach takes CMO gig at liq­uid biop­sy start­up

4 years ago
People

A Pfiz­er win in a heat­ed an­ti-kick­back case could lead to a ‘gold rush’ of bio­phar­ma com­pa­nies sub­si­diz­ing ...

4 years ago
Pharma

FDA slams In­cyte's PD-1 over sin­gle-arm study, low re­sponse and tri­al deaths

4 years ago
FDA+

Gala­pa­gos CSO hits the ex­it as the biotech looks to pick up the pieces af­ter FDA's fil­go­tinib re­jec­tion

4 years ago
People

Y-mAbs push­es back re-sub­mis­sion of its neu­rob­las­toma BLA to end of 2021

4 years ago
FDA+

Chas­ing 'Holy Grail' STAT3 tar­get, Hous­ton start­up re­fu­els with $74M to ze­ro in on liv­er can­cer

4 years ago
Financing

A pair of for­mer MIT re­searchers think they've un­locked the next gen­er­a­tion of mR­NA us­ing syn­bio 'log­ic cir­cuit­s'

4 years ago
Financing
Startups

New FDA doc­u­ments show in­ter­nal dis­sent on Aduhelm ap­proval

4 years ago
FDA+

In­vestors give Orum Ther­a­peu­tic­s' unique take on pro­tein de­graders an­oth­er nudge to­ward the clin­ic

4 years ago
Financing

Third Rock seeds cell ther­a­py start­up with $95M in bid to cure MS

4 years ago
Financing
Startups

San Fran­cis­co-area biotech gets new cash to launch clin­i­cal pro­gram for con­gen­i­tal sug­ar pro­cess­ing dis­ease

4 years ago
Financing

Stephen Elledge's Har­vard lab again proves fruit­ful with the launch of high-through­put an­ti­body start­up

4 years ago
Financing

Yescar­ta goes to Chi­na as Fo­s­un Kite nabs his­toric first CAR-T OK

4 years ago
China
Cell/Gene Tx

With FDA fil­ing for key gene ther­a­py pushed back 6 months, uniQure opens the pock­et­book to re­fresh the pipeline

4 years ago
Deals
FDA+

Wood­cock de­fends Bio­gen's new Alzheimer's drug, says it has more sup­port­ive da­ta than many past ac­cel­er­at­ed ap­provals

4 years ago
FDA+
First page Previous page 685686687688689690691 Next page Last page
A service from the Financial Times